US Patent

US12208092 — Compositions and methods for administering paltusotine to patients with hepatic impairment

Method of Use · Assigned to Crinetics Pharmaceuticals Inc · Expires 2044-03-25 · 18y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods for administering paltusotine to patients with hepatic impairment.

USPTO Abstract

Provided are compositions and methods for administering paltusotine, or a pharmaceutically acceptable salt thereof, to a patient having hepatic impairment.

Drugs covered by this patent

paltusotine-hydrochloride (PALTUSOTINE HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4282`	—	paltusotine-hydrochloride
`U-4282`	—	paltusotine-hydrochloride

Patent Metadata

Patent number: US12208092
Jurisdiction: US
Classification: Method of Use
Expires: 2044-03-25
Drug substance claim: No
Drug product claim: No
Assignee: Crinetics Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.